KOL ENGAGEMENT: AUTHORITY AND INFLUENCE IN A DIGITAL WORLD

Key opinion leaders have traditionally been the most prestigious names in medicine, valued for their input into a drug’s development, for their validation of the scientific approach, and for their influence among prescribers. While this expertise is still sought by pharma, the tightening of conflict-of-interest rules within academia, coupled with new transparency requirements revealing what physicians are paid by industry, are changing the rules of engagement. Meanwhile, a new kind of influencer, the digital opinion leader (DOL), is entering the fray. These are people who may or may not be KOLs in the accepted sense of the word. They could be any of a number of stakeholders who have built up large followings in networks of influence that can make or break a drug in the marketplace.

This report is written to help pharma discern how best to work with the increasingly complex web of influencers that now surrounds all pharmaceutical products. It does this by first examining the effect of transparency on traditional KOL engagement, and then by looking at the power of social media to disrupt established medical hierarchies and forge entirely new pathways of influence.
Executive Summary

Pharma key opinion leaders (KOLs) are taking new forms as social media becomes a more ubiquitous presence in medicine. Physician conversations that may have started in closed and secure physician-only communities are moving into the public space and embracing a wide range of stakeholders, such as patients, nurses, educators, journalists, anyone in fact with an interest in healthcare.

These new influencers are enthusiastic bloggers, tweeters and commentators who have found a platform to amplify their voice in social media. This rapidly changing communications environment is forcing pharma to reconsider how it engages with not only physicians but people from across the entire healthcare spectrum who have an influence in the clinical and political conversations surrounding medicine. Moreover, this rethink comes at a time when pharma companies are compelled, for the first time, to disclose what they pay physicians to speak, advise or conduct research on their behalf.

This report hones in on the changing relationship between authority and influence in medicine and the effect this has on the role of the traditional KOL: physicians valued for their support of pharma’s products and scientific thinking, their research credentials and standing within the medical community.

It considers how their authority can be bolstered in a world awash with opinion while, at the same time, their influence can diminish. Some pharma interviewees suggest the very notion of an opinion leader is a misnomer in an evidence-based world. Others take the view that opinion cannot be ignored because it creates perceptions that, true or not, are a reality that affect pharma sales.

The reality is that these new networks of influence are changing not only perceptions of medicine but how it is practised, even what it means to be ill. Pharma companies needs to be aware of how these networks operate and what their competitors are doing to create opportunities for engagement with the new influencers, the so-called digital opinion leaders (DOLs).

The report opens with an analysis of how new transparency requirements under the Sunshine provisions of the Affordable Care Act might impact engagement with traditional KOLs.

It moves on to present a picture of the new DOLs, stakeholders of influence as evidenced by their impressive online followings that have typically been amassed by a passionate involvement in medical affairs representing constituents who have hitherto been ignored. Connected community oncologists, for example, are challenging the assumption that academics who become expert in one tumour type are they only kind of expert. “[Pharma] are now also looking at where most people are treated in the community setting and asking those people for their opinions, especially for common tumour types that are often treated in the community,” says Dr Mike Thompson, one of the new DOLs who also happens to be a leading physician.

Several other case studies illustrate how the new influencers are opening new avenues in medicine and how they are identified by being at the centre of the most engaged web conversations. The report goes on to examine how their influence varies by therapeutic area and how they can be nurtured via innovative initiatives such as blogging summits, tweetchats, content curation and generally disseminating information from medical conferences and new education formats.

The creation of great digital advocates does not mean abandoning the traditional KOL. It means working with a broader selection of people and helping the real experts expand their influence.
CONTENTS

Interviewees, Figures and Tables ................................................................. 5

Chapter 1: Authority and influence in a connected world .................................. 6
  1.1 The traditional KOL ................................................................................. 6
  1.2 The engaged physician ........................................................................... 7
  1.3 Transparency reveals lower spending on KOLs .................................... 7
  1.4 Case study: GlaxoSmithKline to stop paying external speakers .......... 9

Chapter 2: Multiple stakeholders of influence .................................................. 10
  2.1 The digital opinion leader (DOL) .......................................................... 10
  2.2 Case study: DOL support in gaining market access ............................... 10
  2.3 DOLs are pioneers for change ............................................................... 11
    2.3.1 Case study: Flying the flag for the community oncologist ............... 11
    2.3.2 Incentives to reward pioneers ......................................................... 11
    2.3.3 Case study: The world’s most engaged endocrinologist ............... 12
  2.4 Case study: Physicians, journalists and politicians talk healthcare ........ 12
  2.5 A tipping point ...................................................................................... 14

Chapter 3: Identifying DOLs ........................................................................... 15
  3.1 Influence mapping .................................................................................. 15
  3.2 DOLs at the centre of conversational hubs ............................................. 15
  3.3 Physician DOL identification .................................................................. 16
  3.4 Broader DOL identification .................................................................... 18
  3.5 Physician online networks ...................................................................... 19
    3.5.1 Asking doctors who they look up to ............................................... 19
3.6 DOLs opening new avenues in medicine .............................................. 19
3.7 DOL input varies by therapeutic area .................................................. 20
  3.7.1 Uber connectors ........................................................................... 21
  3.7.2 Clinical differentiation ................................................................... 21
  3.7.3 Free open access medical (FOAM) education movement ............... 21

Chapter 4: New opportunities for engagement ........................................... 22
  4.1 A window on the healthcare world .................................................... 22
  4.2 Roche hosts diabetes blogging summits ........................................... 22
  4.3 Tweetchats ...................................................................................... 22
  4.4 New dissemination opportunities at conferences .............................. 23
  4.5 Using DOLs in content curation ........................................................ 24
  4.6 Campus Sanofi .................................................................................. 24

Chapter 5: Creating great digital advocates .............................................. 25
  5.1 A large and varied pool ................................................................. 25
    5.1.1 Supporting DOLs ....................................................................... 25
  5.2 FDA guidance on social media ......................................................... 26
  5.3 New ways of thinking ..................................................................... 27
Key takeaways ......................................................................................... 28

Acknowledgements ............................................................................... 28

About pharmaphorum media ................................................................. 29
INTERVIEWEES, FIGURES AND TABLES

INTERVIEWEES

Dr Jeffrey D Bloss, senior vice-president, scientific and medical affairs, Astellas

Jeremy Boss, senior global product manager, Novo Nordisk US

Daniel Ghinn, founder, Creation Healthcare

Greg Matthews, managing director, MDigitalLife

Dr Partha Kar, clinical director, diabetes and endocrinology, Portsmouth Hospitals NHS Trust

Dr Tim Ringrose, CEO, M3 Europe

Dr Mike Thompson, community haematologist/oncologist and medical director of Early Cancer Research at Aurora Health Care

FIGURES

Figure 1: Physicians, health reporters and policy makers talking about health, December 2012

Figure 2: Patient-physician engagement hubs

Figure 3: Patients use social networks for high impact conditions

TABLES

Table 1: Top physicians followed by US physicians

Table 2: Top reporters followed by US physicians

Table 3: Top healthcare companies followed by US physicians

Table 4: Top media followed by US physicians

Table 5: Top healthcare companies followed by US physicians
ABOUT PHARMAPHORUM MEDIA

PHARMAPHORUM

pharmaphorum facilitates productive engagement for pharma, bringing healthcare together to drive medical innovation. We facilitate this using both our publication channels and bespoke consultancy.

Channel offerings

Through pharmaphorum.com and associated social media, we publish thought leadership media from industry experts, healthcare providers and patient organisations to better inform the pharma industry and drive engagement.

Collectively, these channels provide pharma with:

- Essential news, opinions and insights
- Training / career development
- Curated external media, including jobs, events and press releases
- Visibility and connectivity with other healthcare stakeholders

Consultancy offerings

We support pharma, service providers and broader healthcare organisations to communicate with key stakeholders through high-quality content and truly engaging social media strategies. Clients benefit from our strong networks, first-hand industry experience and access to publication partners. We understand the importance of content and social media engagement as we live and breathe it every day.

Our offerings include:

- Engagement strategy
- Content production / facilitation
- Healthcare / pharma social media
- Meetings / round table discussions
- Content dissemination

For more information please visit:
www.pharmaphorum.com/our-services

PHARMAPHORUM PREMIUM MEDIA

Launched in 2014, pharmaphorum premium media draws on our expert content production capabilities, deep pharma expertise and connectivity across healthcare to publish unique high-value media, which informs pharma industry personnel on critical aspects of their business. Available for purchase by both individuals and organisations, pharmaphorum premium media provides the competitive edge only afforded by access to the opinions and insights of key industry experts.

For more information please visit: www.pharmaphorum.com/premium